Mental health practice marketing operates under compliance rules that are in some ways stricter than other healthcare categories. HIPAA considerations are heightened because mental health treatment data is particularly sensitive. Platform advertising policies for mental health content are among the most restrictive. And FTC substantiation rules apply to specific treatment outcome claims. This post covers therapy, psychiatry, and online mental health platform marketing.
Enhanced HIPAA considerations
Mental health information is treated as particularly sensitive under HIPAA. Psychotherapy notes have additional protections beyond general PHI. This affects marketing in several ways:
- Testimonials and patient stories in mental health marketing carry higher HIPAA sensitivity.
- Authorization requirements are particularly important.
- Responses to online reviews risk disclosing sensitive information.
- Aggregate or anonymized patient-outcome marketing requires careful de-identification review.
Treatment outcome claims
Claims about mental health treatment outcomes need substantiation:
- “Cures depression” is disease-treatment territory; therapy does not “cure” depression in the sense that language implies.
- “Proven to work” or “clinically proven” needs specific evidence for specific modalities.
- Success-rate claims need substantiation based on published literature or specific practice data.
Compliant framing acknowledges therapy as clinical care with variable individual outcomes. “Evidence-based treatment for depression and anxiety” is defensible when the modalities offered have an evidence base.
Platform policy restrictions
Platform policies for mental health content are particularly restrictive:
- Meta. Mental health ads face specific policy restrictions; suicide-related content faces additional community guidelines.
- Google Ads. Mental health advertising often requires specific certification; addiction treatment requires LegitScript.
- TikTok. Mental health content faces community guidelines in addition to advertising policy.
Crisis and suicide-related marketing
Marketing that targets patients in acute crisis raises specific concerns:
- FTC heightened-scrutiny considerations for marketing to vulnerable populations.
- Professional ethics considerations (APA, NASW) on commercial targeting of crisis contexts.
- Platform policy restrictions on crisis-related commercial content.
Crisis resource provision (988, crisis hotlines) is appropriate in mental health content; commercial conversion targeting patients in crisis is not.
Online and telehealth mental health
Online therapy platforms and telehealth psychiatry face additional rules:
- State licensure of providers for patients in specific states.
- Prescribing considerations for telehealth psychiatry, including controlled-substance Ryan Haight Act considerations.
- Clear marketing of the care model (async vs sync, therapy vs psychiatry, prescribing vs non-prescribing).
- State-specific telehealth rules that vary.
Therapy modality marketing
Specific modality marketing (CBT, EMDR, DBT, ACT, psychodynamic, somatic) needs accuracy:
- Modality certifications require specific training; claiming modality specialization needs accurate credentials.
- Evidence base varies by modality; claims about efficacy should reflect the actual research.
- “Certified” in specific modalities often has specific certifying organizations; casual usage can be misleading.
Psychiatric medication marketing
Psychiatry practices marketing specific medications face prescription-drug advertising considerations. Branded medication marketing (SSRI brand names, ketamine, esketamine, stimulants) falls under the same rules as other prescription drug advertising.
See our ketamine clinic marketing compliance post for specific considerations in that subcategory.
Compliant mental health practice marketing
- Clinical-approach framing. Describe the therapy modalities, practitioner training, and care structure.
- Evidence-based language where supported.“Evidence-based treatment approaches” with specific named modalities when appropriate.
- Accurate outcome framing.“Many patients find meaningful improvement through therapy; individual experiences vary” is honest and compliant.
- Clear service model description.Especially for online platforms - what service, with whom, in what format.
- Crisis resource inclusion. Content that touches on crisis topics should include professional resources (988, crisis lines).
- HIPAA-authorized testimonials only.Generic experience framing rather than specific-condition recovery stories.
Frequently asked questions
Can I share patient success stories generally?
With HIPAA-compliant authorization and appropriate framing. Mental health testimonials face higher HIPAA sensitivity than other specialties; authorization should be particularly specific.
What about patient-written reviews on external platforms?
Patients can post reviews on their own. You should not repost or republish without HIPAA authorization. Responding requires generic framing that doesn’t confirm patient status.
Does therapy marketing need FDA consideration?
Typically no, for non-medication therapy. FDA considerations emerge when digital therapeutics (FDA-regulated software as medical device), wearables, or medication-related content is involved.
How should practice bios discuss provider specialization?
Accurately. “Specializes in treating adolescents with anxiety and depression” is defensible when true. “Specialist” with implication of board certification needs the actual credential.
What about online therapy platform comparison marketing?
Comparative marketing between platforms faces FTC comparative-claim substantiation rules. “Better than [competitor]” claims need head-to-head evidence.
Are there specific ethics considerations from professional associations?
Yes. APA, APA (psychiatry), NASW, and state licensing boards have ethics codes that affect marketing. Many include restrictions beyond FTC rules (e.g., on testimonials, on solicitation practices, on comparative advertising).